Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments.
biomarkers
combined therapy
immunotherapy
molecular subtypes
muscle-invasive bladder cancer
neoadjuvant chemotherapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
04
2022
accepted:
22
06
2022
entrez:
8
8
2022
pubmed:
9
8
2022
medline:
9
8
2022
Statut:
epublish
Résumé
Urothelial carcinoma of the bladder is one of the most prevalent cancers worldwide, diagnosed as muscle invasive in 25% of cases. Although several studies have demonstrated an overall 5% absolute survival benefit at 5 years with cisplatin-based combination neoadjuvant treatment, administration of chemotherapy prior to radical cystectomy (RC) in muscle-invasive bladder cancer (MIBC) patients is still a matter of debate. This may be due to the perceived modest survival benefit, cisplatin-based chemotherapy ineligibility, or fear of delaying potentially curative surgery in non-responders. However, immunotherapy and novel targeted therapies have shown to prolong survival in advanced disease and are under investigation in the neoadjuvant and adjuvant settings to reduce systemic relapse and improve cure rates. Genomic characterization of MIBC could help select the most effective chemotherapeutic regimen for the individual patient. Large cohort studies on neoadjuvant treatments with immune checkpoint inhibitors (ICIs) and molecular therapies, alone or combined with chemotherapy, are ongoing. In this review, we trace the development of neoadjuvant therapy in MIBC and explore recent advances that may soon change clinical practice.
Identifiants
pubmed: 35936721
doi: 10.3389/fonc.2022.912699
pmc: PMC9353067
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
912699Informations de copyright
Copyright © 2022 Roviello, Catalano, Santi, Santoni, Galli, Amorosi, Polom, De Giorgi and Nesi.
Déclaration de conflit d'intérêts
UG received honoraria for advisory boards or invited speaker fees from Pfizer, BMS, MSD, PharmaMar, Astellas, Bayer, Ipsen, Novartis, Roche, Clovis, AstraZeneca, institutional research grants from AstraZeneca, Sanofi and Roche. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.
Références
Oncology (Williston Park). 2018 May 15;32(5):228-34
pubmed: 29847853
J Urol. 2004 Feb;171(2 Pt 1):561-9
pubmed: 14713760
Oncogene. 2013 Jan 10;32(2):222-33
pubmed: 22349828
Korean J Intern Med. 2020 Jul;35(4):834-853
pubmed: 32668516
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Nutrients. 2021 Dec 14;13(12):
pubmed: 34960023
Clin Cancer Res. 2020 Oct 1;26(19):5120-5128
pubmed: 32532789
Oncogene. 2003 Oct 20;22(47):7265-79
pubmed: 14576837
J Clin Oncol. 2018 Dec 1;36(34):3353-3360
pubmed: 30343614
Eur Urol. 2016 Mar;69(3):384-8
pubmed: 25636205
J Clin Oncol. 2014 Jun 20;32(18):1889-94
pubmed: 24821883
Eur Urol. 2004 Mar;45(3):297-303
pubmed: 15036674
J Clin Oncol. 2020 Feb 10;38(5):406-414
pubmed: 31794323
Am J Cancer Res. 2015 Jan 15;5(2):854-68
pubmed: 25973322
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
J Natl Cancer Inst. 2019 Jun 1;111(6):538-549
pubmed: 30859213
Nat Med. 2020 Dec;26(12):1839-1844
pubmed: 33046870
Lancet. 2018 Feb 24;391(10122):748-757
pubmed: 29268948
Lancet Oncol. 2017 Mar;18(3):312-322
pubmed: 28131785
Cancer Med. 2020 Dec;9(24):9365-9372
pubmed: 33098265
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Int J Cancer. 2000 Sep 20;89(5):453-7
pubmed: 11008208
Eur Urol Focus. 2021 Nov;7(6):1347-1354
pubmed: 32771446
Nat Med. 2019 Nov;25(11):1706-1714
pubmed: 31686036
Int J Mol Sci. 2018 Oct 19;19(10):
pubmed: 30347758
Lancet Oncol. 2018 Jan;19(1):51-64
pubmed: 29217288
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275-80
pubmed: 20160101
Eur Urol Oncol. 2020 Aug;3(4):544-547
pubmed: 32165095
Int J Clin Oncol. 2020 May;25(5):818-830
pubmed: 31549270
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Lancet. 2003 Jun 7;361(9373):1927-34
pubmed: 12801735
JCO Precis Oncol. 2018;2018:
pubmed: 30234181
J Clin Oncol. 2001 Feb 1;19(3):666-75
pubmed: 11157016
Clin Genitourin Cancer. 2020 Oct;18(5):387-394
pubmed: 32273235
Eur Urol Oncol. 2018 Dec;1(6):486-500
pubmed: 31158093
Eur Urol. 2020 Apr;77(4):420-433
pubmed: 31563503
Clin Cancer Res. 2012 Jun 15;18(12):3377-86
pubmed: 22553347
Eur Urol. 2019 Aug;76(2):200-206
pubmed: 31092337
Cancer Cell. 2014 Feb 10;25(2):152-65
pubmed: 24525232
Adv Urol. 2013;2013:317190
pubmed: 24382958
Nat Rev Cancer. 2012 Dec;12(12):801-17
pubmed: 23175119
CA Cancer J Clin. 2020 Sep;70(5):404-423
pubmed: 32767764
Am J Obstet Gynecol. 2016 Aug;215(2):227.e1-227.e16
pubmed: 26899906
J Natl Compr Canc Netw. 2020 Mar;18(3):329-354
pubmed: 32135513
J Clin Oncol. 2018 Jul 1;36(19):1949-1956
pubmed: 29742009
Target Oncol. 2019 Feb;14(1):15-32
pubmed: 30694442
Cancer. 2008 Nov 1;113(9):2471-7
pubmed: 18823036
Clin Cancer Res. 2017 Jul 15;23(14):3610-3618
pubmed: 28137924
Ann Oncol. 2011 Jan;22(1):139-144
pubmed: 20603439
Eur Urol. 2019 Feb;75(2):231-239
pubmed: 30290956
Ann Thorac Surg. 2018 Apr;105(4):1008-1016
pubmed: 29453000
J Clin Oncol. 2020 Aug 10;38(23):2658-2666
pubmed: 32552471
Eur Urol. 2020 May;77(5):576-580
pubmed: 31911010
Nature. 2014 Mar 20;507(7492):315-22
pubmed: 24476821
Urol Oncol. 2021 Apr;39(4):235.e15-235.e21
pubmed: 33071107
Cancer. 2015 Aug 1;121(15):2586-93
pubmed: 25872978
Cancers (Basel). 2021 Aug 31;13(17):
pubmed: 34503220
Ann Oncol. 2020 Dec;31(12):1755-1763
pubmed: 32979511
Ann Oncol. 2007 Mar;18(3):522-8
pubmed: 17229776
Ann Oncol. 2019 Jun 1;30(6):970-976
pubmed: 31050707
J Immunother Cancer. 2017 Nov 21;5(1):94
pubmed: 29157296
Eur Urol. 2017 Oct;72(4):544-554
pubmed: 28390739
Cell. 2017 Oct 19;171(3):540-556.e25
pubmed: 28988769
Eur Urol Oncol. 2020 Jun;3(3):351-359
pubmed: 32423837
J Urol. 1988 Mar;139(3):470-4
pubmed: 3343728
J Clin Oncol. 2005 Jul 20;23(21):4602-8
pubmed: 16034041
Int J Mol Sci. 2020 Oct 26;21(21):
pubmed: 33114616
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
Cancer Discov. 2014 Oct;4(10):1140-53
pubmed: 25096233
JAMA Oncol. 2017 Sep 14;3(9):e172411
pubmed: 28817753
Eur Urol. 2015 Dec;68(6):959-67
pubmed: 26238431
Hematol Oncol Clin North Am. 2015 Apr;29(2):301-18, ix
pubmed: 25836936
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Eur Urol. 2021 Jan;79(1):82-104
pubmed: 32360052
Lancet. 2020 May 16;395(10236):1547-1557
pubmed: 32416780
J Clin Oncol. 2018 Jun 10;36(17):1685-1694
pubmed: 29489427
JAMA Oncol. 2016 Aug 1;2(8):1094-6
pubmed: 27310333
Nat Med. 2020 Apr;26(4):475-484
pubmed: 32273608
J Urol. 2019 Jul;202(1):30
pubmed: 30925134
J Urol. 2013 May;189(5):1682-6
pubmed: 23123547
Eur Urol. 2021 Feb;79(2):214-221
pubmed: 32868138
Clin Genitourin Cancer. 2019 Jun;17(3):e712-e719
pubmed: 31085058
Eur Urol. 2019 Jun;75(6):961-964
pubmed: 30851984
Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3110-5
pubmed: 24520177
PLoS One. 2016 Sep 09;11(9):e0161779
pubmed: 27610613
J Clin Oncol. 2022 Apr 20;40(12):1312-1322
pubmed: 35089812
N Engl J Med. 2003 Aug 28;349(9):859-66
pubmed: 12944571
Eur Urol. 2005 Aug;48(2):202-5; discussion 205-6
pubmed: 15939524
J Clin Oncol. 2014 Jun 20;32(18):1895-901
pubmed: 24821881
Eur Urol. 2015 Jan;67(1):165-170
pubmed: 24472710
J Exp Clin Cancer Res. 2019 Jun 13;38(1):255
pubmed: 31196207
Clin Cancer Res. 2019 Aug 15;25(16):5082-5093
pubmed: 30224344
Lancet. 1999 Aug 14;354(9178):533-40
pubmed: 10470696
J Clin Oncol. 2019 Oct 10;37(29):2592-2600
pubmed: 31356140
J Clin Oncol. 2011 Jun 1;29(16):2171-7
pubmed: 21502557
Clin Cancer Res. 2008 Aug 1;14(15):4800-8
pubmed: 18676751
JCI Insight. 2016 Mar 17;1(3):e85902
pubmed: 27699256
Cancers (Basel). 2020 Jul 03;12(7):
pubmed: 32635360